Pages
- Contact us
- Data Privacy Policy
- Inserm Transfert – Your partner for value creation and technology transfert in Life Sciences
- Legal notice
- Sitemap
- Researchers portal
- Company portal
- Inserm Transfert
- News – Press
Posts by category
- Category: Archives News
- Category: News - Press
- Palmarès de l’innovation : l’Inserm se distingue une nouvelle fois par son dynamisme et ses résultats
- 2èmes rencontres du parcours pré-entrepreneurial : Inserm Transfert dévoile de nouveaux dispositifs de soutien à la création d’entreprise de croissance
- L’Inserm, Inserm Transfert et la SATT Toulouse Tech Transfer (TTT) signent un accord de partenariat pour le financement de projets de maturation à Toulouse
- RaDiCo (Inserm) et Boehringer Ingelheim France annoncent un partenariat autour de la Fibrose Pulmonaire Idiopathique
- Un modèle animal inédit pour accélérer la lutte contre la maladie d’Alzheimer
- OSE Immunotherapeutics annonce un accord de collaboration avec option de licence avec l’Inserm sur une nouvelle immunothérapie du cancer ciblant les cellules myéloïdes
- MedImmune, Inserm and Inserm Transfert Renew Strategic Research Partnership
- ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones including Positive Phase 1b Clinical Study Data
- TxCell and Inserm collaborate to develop new CAR-Tregs in transplantation and multiple sclerosis
- Classement 2016 de l’Office européen des brevets: doublé gagnant pour l’Inserm
- Prévention et traitement des accidents vasculaires : MSDAVENIR, l’AP-HP et l’Inserm signent deux conventions de financement pour les programmes de recherche SAVE BRAIN et SURVI
- Projet CARBAMAT : vers une avancée médicale pour limiter la résistance aux antibiotiques
- Stimunity signs an Exclusive License Agreement with Institut Curie and Inserm
- MSD France and Lille University Regional Hospital Centre supported by Inserm Transfert sign a partnership agreement on the FREGAT Clinical-Biological database to improve the management of patients suffering from oesophago-gastric cancers.
- “SANOFI-INSERM HBV Cure program”: a medical, academic and pharmaceutical alliance for research into hepatitis B
- Jean-Laurent Casanova, specialist in genetics of infectious diseases, winner of the Inserm Grand Prix 2016 prize.
- TxCell acquires the exclusive worldwide rights on a new population of regulatory T cells from Inserm Transfert.
- Pierre Fabre and Cordeliers Research Centre Enter into strategic partnership to identify new therapeutic targets in immuno-oncology
- NAREB: a EU-funded research project for combating antibiotic resistance
- Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
- Creation of HalioDx
- European Patent Office rankings for 2014: Inserm 6th in France for patent applications, 1st in Europe for academic patent applications in biomedical research
- Advanced Biological Laboratories Enters into Worldwide Exclusive License Agreement for HIV Tropism Determination Technology with Inserm and Inserm Transfert SA, and the Centre Hospitalier Universitaire de Toulouse
- Huntington’s disease: therapeutic potential of triheptanoin confirmed
- Christos Chatziantoniou at Inserm UMR 1155 Wins GSK’s Discovery Fast Track Challenge to Investigate Chronic Kidney Disease
- Inserm Transfert (France) and Translational Research Informatics Center (Japan) enter into international cooperation agreement regarding translational researches
- Cécile Tharaud appointed as President and Managing Partner of Inserm Transfert Initiative
- Mrs Pascale Augé appointed as Chief Executive Officer, Inserm Transfert
- ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology
- Inserm Transfert and GSK sign a worldwide license agreement on novel immune checkpoint modulators for the treatment of cancer
- DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin® for Refractory Hemophilia A Disease
- Inserm Transfert and MassBio announce a partnership to foster innovation, technology transfer and entrepreneurship between France and Massachusetts (USA)
- QIAGEN Marseille acquires exclusive rights from Inserm Transfert SA and Inserm on HSP110 mutations for colorectal cancer
- Roche, Fondation FondaMental and Inserm partners to improve understanding of autism mechanims.
- Imagine Institute and GlaxoSmithKline (GSK) Agree on a Collaborative Partnership for Drug Discovery for rare diseases
- DBV Technologies and Centre d’Immunologie de MarseilleLuminy (CIML) enter in a Collaboration Agreement
- Launch of ENTENTE, the first European network to boost knowledge transfer activity in health research in academic and governmental organisations and industry-academia collaboration
- Sebia partners with Inserm and Inserm Transfert to develop a unique diagnostic test for haemoglobin diseases
- La cohorte CKD-REIN, financée dans le cadre du Programme Investissements d’avenir, fédère un partenariat avec 6 acteurs industriels majeurs dans le domaine de la néphrologie
- Roche, the French National Agency for Research on AIDS and Viral Hepatitis, Baylor Research Institute and Inserm Transfert Establish Strategic Collaboration to Develop Therapeutic Vaccines for Chronic Infectious Diseases
- Covance, Inserm Transfert SA, and Inserm Transfert Initiative Enter Four-Year Scientific Agreement
- “Investments for the future” program: Fonds National d’Amorçage’s first investment is in Inserm Transfert Initiative, a seed capital company specialising in life sciences and healthcare
- MEDIMMUNE, INSERM AND INSERM TRANSFERT ANNOUNCE STRATEGIC COLLABORATION TO FUND AND CONDUCT MEDICAL SCIENCE RESEARCH
- Inserm Transfert annonce 70% de taux de réussite au 4e appel à proposition du 7e PCRD et renforce son activité auprès de chercheurs internationaux
- Inserm Transfert annonce l’obtention de la certification Qualité ISO 9001-2008 pour ses activités de management de projets de recherche collaborative
- INSERM TRANSFERT AND INNATE PHARMA ENTER INTO AN INNOVATIVE PARTNERSHIP FOR THE DEVELOPMENT OF NEW ANTIBODIES FOR THE TREATMENT OF CANCER AND INFLAMMATORY OR AUTOIMMUNE DISEASES
Jobs
Portfolio
- EE-ASI
- EBOVAC 2
- EBOLAMODRAD
- CARMMA
- AGEDBRAINSYSBIO
- EHVA
- ENSAT-HT
- ERINHA
- GENEGRAFT
- JPND
- MEDIT-AGEING
- METACARDIS
- IMMUNOSCORE
- COHORTES
- MEDIMMUNE
- SILTISS
- ILIAD
